February

Prokarium, the Keele-based synthetic biology company that has developed Vaxonella, an oral, thermostable vaccine delivery platform, today announced the completion of a $10 million investment round.

Keele’s MCIL programme has helped business leader Dave Purkiss take his growing design consultancy to the next level.

A Staffordshire-based company is looking to transform the way that patients manage and monitor their asthma, thanks to support from Keele University.